KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Current Leases (2019 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Current Leases for 7 consecutive years, with $18.6 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 7.46% to $18.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.6 million through Dec 2025, up 7.46% year-over-year, with the annual reading at $18.6 million for FY2025, 7.46% up from the prior year.
  • Current Leases hit $18.6 million in Q4 2025 for CRISPR Therapeutics AG, up from $18.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $18.6 million in Q4 2025 to a low of $8.3 million in Q2 2022.
  • Historically, Current Leases has averaged $15.0 million across 5 years, with a median of $15.8 million in 2022.
  • Biggest five-year swings in Current Leases: tumbled 47.92% in 2022 and later surged 79.42% in 2023.
  • Year by year, Current Leases stood at $12.2 million in 2021, then skyrocketed by 30.3% to $15.8 million in 2022, then dropped by 1.37% to $15.6 million in 2023, then increased by 10.64% to $17.3 million in 2024, then rose by 7.46% to $18.6 million in 2025.
  • Business Quant data shows Current Leases for CRSP at $18.6 million in Q4 2025, $18.3 million in Q3 2025, and $18.0 million in Q2 2025.